Latest VisionGate Inc. Stories

PHOENIX, Nov. 6, 2012 /PRNewswire/ -- VisionGate, Inc., today reported that it presented new data confirming that its breakthrough Cell-CT(TM) platform for the automated analysis of three dimensional (3D) images of cells can identify disease-associated features that are not visible using 2D cytology. The data were presented this week by VisionGate founder and CEO Alan Nelson, PhD, at the 60th Annual Scientific Meeting of the American Society of Cytopathology. The Cell-CT...

PHOENIX, Jan. 6, 2012 /PRNewswire/ -- VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer and other applications, today reported that it has achieved full automation of its Cell-CT(TM) system, a proprietary imaging platform that generates high-resolution 3D biosignatures from intact cells. Development of the fully automated system was funded in part by a $2.6 million grant from the National Institutes...

PHOENIX, Oct. 19, 2011 /PRNewswire/ -- VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer, today reported that it has raised approximately $2 million in the first tranche of a financing round. The company also announced that it has entered into a collaboration with the Sheba Medical Center in Israel to evaluate whether VisionGate's LuCED(TM) test can reduce false positive results when used in conjunction with x-ray computed...

IASLC presentation addresses key issue from landmark NLST lung cancer study -- how to manage high rate of false positive results; lays out protocol for adjunctive use of noninvasive diagnostic test to clarify false positives from CT screeningVisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer, today announced that it will present data showing how adjunctive use of its LuCEDâ„¢ test can improve the utility of low dose x-ray...

AMSTERDAM and PHOENIX, July 4, 2011 /PRNewswire/ -- VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer, today announced that it will present data showing how adjunctive use of its LuCED(TM) test can improve the utility of low dose x-ray computed tomography (CT) screening for the early detection of lung cancer in high risk individuals. LuCED uses VisionGate's revolutionary automated 3D cell imaging platform, the Cell-CT(TM), which...

Eric Seibel, a UW mechanical engineering associate professor, and his colleagues have worked in collaboration with VisionGate, Inc., a privately held company in Gig Harbor, Wash., that holds the patents on the technology. The machine works by rotating the cell under the microscope lens and taking hundreds of pictures per rotation, and then digitally combining them to form a single 3-D image.The 3-D visualizations could lead to big advances in early cancer detection, since clinicians today...